Sleep Specialists, LLC, a medical device company specializing in sleep therapy, announced that their FDA cleared Zzoma Positional Device was used in a clinical trial examining the influence of gender on the effectiveness of positional therapy in the treatment of patients with positional obstructive sleep apnea (OSA). (Results were presented at the Annual Meeting of the Associated Professional Sleep Societies in Boston Massachusetts).
The new study was conducted out of Temple University in Philadelphia and included patients previously diagnosed with positional sleep apnea. Following their baseline polysomnography (PSG), all patients underwent a treatment night PSG using the Zzoma Positional Device. There were three major findings. First, baseline characteristics and disease severity are similar in male as compared to female patients with positional OSA. Second, the use of Zzoma resulted in a similar relative change and normalization of AHI in males as compared to female patients. Third, sleep quality and nocturnal oxygenation remained stable in both male and female patients with Zzoma. The findings concluded that positional therapy, as treatment, appears to be equally effective at normalizing sleep disordered breathing in male as compared to female patients diagnosed with positional OSA.
Zzoma is a device worn around the upper torso that keeps patients asleep on their sides by preventing supine or “on-the-back” sleeping. Clinicians may prescribe Zzoma as a first line therapy or as an alternative for patients who cannot tolerate oral appliances or Continuous Positive Airway Pressure (CPAP) therapy.
“For a very long time we questioned how our female patients sleep compared to our male,” says Sila Yesilsoy, COO of Sleep Specialists, LLC. “The new study confirmed that Zzoma is an appropriate solution for both genders and we are happy to report that.”